1. Home
  2. FAMI vs MIRM Comparison

FAMI vs MIRM Comparison

Compare FAMI & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Farmmi Inc.

FAMI

Farmmi Inc.

HOLD

Current Price

$1.26

Market Cap

7.8M

ML Signal

HOLD

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$77.57

Market Cap

4.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FAMI
MIRM
Founded
2015
2018
Country
China
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.8M
4.2B
IPO Year
2018
2019

Fundamental Metrics

Financial Performance
Metric
FAMI
MIRM
Price
$1.26
$77.57
Analyst Decision
Strong Buy
Analyst Count
0
11
Target Price
N/A
$92.45
AVG Volume (30 Days)
6.1K
811.9K
Earning Date
01-26-2026
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$43,831,754.00
$471,794,000.00
Revenue This Year
N/A
$53.78
Revenue Next Year
N/A
$19.91
P/E Ratio
N/A
N/A
Revenue Growth
N/A
53.66
52 Week Low
$1.26
$36.88
52 Week High
$7.07
$82.58

Technical Indicators

Market Signals
Indicator
FAMI
MIRM
Relative Strength Index (RSI) 34.90 58.25
Support Level $1.38 $77.99
Resistance Level $1.49 $82.58
Average True Range (ATR) 0.10 3.33
MACD -0.01 0.71
Stochastic Oscillator 0.00 74.62

Price Performance

Historical Comparison
FAMI
MIRM

About FAMI Farmmi Inc.

Farmmi Inc is an investment holding company. Through its subsidiaries, it acts as a supplier of agricultural products. It is an agricultural technology enterprise focused on its supply chain platform by promoting edible mushroom products and agriculture technology. Its product offerings include tapioca, corn, red dates, shiitake mushrooms, mu er fungus, other edible fungi, and other agricultural products. Geographically, the company's products are sold in China, Southeast Asia, Japan, North America, Europe, and the Middle East under the Forasen and Farmmi brands.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: